Patients must meet all of the following inclusion criteria to be eligible for inclusion in
the study:
1. Confirmed diagnosis of AML on or after 01 January 2012 through Clinical Research Nurse
(CRN) review of provider documentation of AML diagnosis in the medical record.
2. Receipt of non-intensive therapy at any point during first line therapy following
initial AML diagnosis. For this study, non-intensive therapy will be defined as 1 of
the following agents, alone or in combination with any other agent:
1. AZA
2. GLAS
3. VEN
3. Age ≥18 years at initial diagnosis of AML.
Patients meeting any of the following criteria will not be included in the study:
1. Record of 1 or more of the following confounding diagnoses at any point before or after
AML diagnosis: Acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive
systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia;
dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.